)
Invivyd (IVVD) investor relations material
Invivyd Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
PEMGARDA Q3 revenue was $15.449M, up 18% from $13.129M, while net loss widened to $33.468M from $10.470M as R&D and SG&A increased.
Cash and cash equivalents were $126.398M at September 30, 2026; without future external financing, available cash is not expected to fund operations and capital needs beyond one year, raising substantial doubt about going concern.
VYD2311 advanced in Phase 3 and Phase 2 programs; DECLARATION interim data and a regulatory update were expected in Q4 2026 following FDA dialogue on the accelerated approval approach.
Financial highlights
Q3 product revenue was $15.449M vs. $13.129M YoY; nine-month revenue was $43.478M vs. $36.219M, driven by higher PEMGARDA demand.
Q3 R&D expense rose to $18.7M from $8.0M and SG&A to $30.3M from $15.0M, primarily reflecting increased clinical and commercial activity.
Q3 operating loss was $34.679M vs. $11.023M; nine-month operating loss was $123.635M vs. $43.005M.
Nine-month operating expenses rose to $167.113M from $79.224M, led by R&D of $78.834M and SG&A of $84.931M.
Nine-month net loss was $119.261M vs. $41.419M; Q3 and nine-month loss per share were $0.10 vs. $0.06 and $0.38 vs. $0.30, respectively.
Outlook and guidance
DECLARATION interim analyses of antibody titers, pharmacokinetics, immunogenicity and safety were planned for Q4 2026; positive results could support a BLA under the accelerated approval pathway, with clinical events continuing as confirmatory data.
Initial FLINTLOCK data are expected in mid-2027; the Phase 2 trial evaluates high-dose VYD2311 in Long COVID or Post-Vaccination Syndrome.
VMS063 was expected to reach IND readiness in H2 2026, with clinical development anticipated in 2027; production scale-up is underway.
PEMGARDA’s EUA is set to terminate June 29, 2027; FDA discussions on next steps continue.
Expenses are expected to rise with clinical development, manufacturing and commercialization; funding may come from revenue, equity, grants, debt or partnerships.
- LIBERTY showed superior VYD2311 tolerability and ~2.5x higher titers with vaccination.IVVD
Study result - VYD2311 aims to transform infectious disease prevention with scalable, flexible antibody protection.IVVD
H.C. Wainwright 28th Annual Global Investment Conference - Q2 2026 revenue grew 21% but net loss widened, with future revenue at risk from PEMGARDA EUA expiry.IVVD
Q2 2026 - VYD2311 advances toward late-stage COVID-19 prevention, with broad pipeline and market ambitions.IVVD
H.C. Wainwright “HCW @ Home” Series - Antibody-based prevention aims to surpass vaccines in protection, safety, and patient preference.IVVD
Jefferies Global Healthcare Conference 2026 - Directors were elected and the auditor ratified, with no additional proposals or questions.IVVD
AGM 2026 - Q3 revenue up 41% YoY to $13.1M, net loss narrowed, and pivotal VYD2311 trials set for year-end.IVVD
Q3 2025 - VYD2311 aims for durable, safe COVID protection with strong efficacy in pivotal prevention trials.IVVD
Study Update - Q2 PEMGARDA launch drove $2.3M revenue, but cash runway is under one year.IVVD
Q2 2024
)
)
)
)
)
)
)
)